

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The Phase III MA17R trial evaluating extension of adjuvant letrozole for 5 years after completion of an initial 5 years of AI therapy alone or preceded by tamoxifen in early-stage BC demonstrated no improvement in disease-free survival with the extension of AI therapy.
 - True
 - False
- The combination of pertuzumab with trastuzumab and docetaxel is FDA approved as _____ for patients with HER2-positive _____.
 - Adjuvant therapy; early BC
 - Neoadjuvant therapy; early BC
 - First-line therapy; mBC
 - All of the above
 - Both a and b
 - Both b and c
- Data presented at ASCO 2016 from the Phase III PALOMA-2 trial of palbociclib and letrozole versus letrozole alone for patients with ER-positive, HER2-negative advanced BC who had not received prior systemic therapy for their advanced disease demonstrated a statistically significant improvement in the primary study endpoint of progression-free survival (PFS) for patients who received palbociclib.
 - True
 - False
- Single-agent activity has been reported with which of the following CDK4/6 inhibitors in patients with ER-positive, HER2-negative mBC?
 - Abemaciclib
 - Palbociclib
 - Ribociclib
 - None of the above
- Which of the following is the mechanism of action of fulvestrant?
 - Selective estrogen receptor degrader
 - Selective estrogen receptor modulator
 - Both a and b
 - Neither a nor b
- The Phase III MONARCH 2 trial is evaluating _____ with or without abemaciclib in patients with ER-positive, HER2-positive locally advanced or metastatic BC.
 - Anastrozole
 - Fulvestrant
 - Letrozole
 - All of the above
- Which of the following toxicities is exhibited to a much greater extent in patients receiving abemaciclib than in those receiving palbociclib for ER-positive mBC?
 - Diarrhea
 - Fatigue
 - Myelosuppression
 - All of the above
- The Phase III BELLE-2 study evaluating fulvestrant with or without buparlisib (BKM120) in postmenopausal women with endocrine-resistant ER-positive, HER2-negative advanced BC reported a significant improvement in PFS for patients with PIK3CA mutations who received buparlisib.
 - True
 - False
- Which of the following PI3K inhibitors is actively under Phase III investigation for patients with endocrine-resistant ER-positive advanced BC?
 - Alpelisib
 - Taselisib
 - Both a and b
 - Neither a nor b
- The goal of the MINDACT trial, for which initial results were recently published, was to evaluate the benefit of genomic profiling with the _____ in addition to standard clinical-pathological criteria for patients with early BC and 0 to 3 positive lymph nodes who might safely forgo chemotherapy without compromising outcome.
 - BCI
 - 70-gene signature
 - 21-gene signature